Nutrilis Healthcare Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
as on 31-12-2024
- Paid Up Capital ₹ 0.10 M
as on 31-12-2024
- Company Age 12 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -13.86%
(FY 2022)
- Profit 102.62%
(FY 2022)
- Ebitda -51.43%
(FY 2022)
- Net Worth 0.15%
(FY 2022)
- Total Assets 3.37%
(FY 2022)
About Nutrilis Healthcare
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Dilipkumar Jain and Gaurav Jain serve as directors at the Company.
- CIN/LLPIN
U24239GJ2012PTC069403
- Company No.
069403
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Mar 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Nutrilis Healthcare Private Limited offer?
Nutrilis Healthcare Private Limited offers a wide range of products and services, including Sexual Wellness Products, Fertility Enhancer, Respiratory System Drugs, Anti Asthma Drug, Amoxicillin drugs, Amoxicillin Potassium Clavulanate Tablet, Eye Drops, Carboxymethylcellulose Sodium Eye Drops, Asthma Inhaler, Budesonide Inhaler & Nebulizer.
Who are the key members and board of directors at Nutrilis Healthcare?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gaurav Jain  | Director | 15-Feb-2020 | Current |
| Dilipkumar Jain | Director | 15-Feb-2020 | Current |
Financial Performance of Nutrilis Healthcare.
Nutrilis Healthcare Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 13.86% decrease. The company also saw a substantial improvement in profitability, with a 102.62% increase in profit. The company's net worth moved up by a moderate rise of 0.15%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nutrilis Healthcare?
In 2020, Nutrilis Healthcare had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Nutrilis Healthcare?
Nutrilis Healthcare has a workforce of 3 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nutrilis Healthcare, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nutrilis Healthcare's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
